r/biotech
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.
- upvotes
- 300
- comments
- 59
Extracted from these lines
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask.
From the post
[comment u/NoGoat3930] Salveen Richter is the name of the analyst. We all deserve credit for our ideas and it's offensive that you left out this info.
[comment u/Airocketfish] Maybe we could save a lot of money if we don't support a company like Goldman Sachs.